Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Galapagos NV
  6. News
  7. Summary
    GLPG   US36315X1019

GALAPAGOS NV

(GLPG)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galapagos NV - GLPG

02/19/2021 | 01:06am EDT

NEW YORK, Feb. 19, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Galapagos NV ("Galapagos" or the "Company") (NASDAQ: GLPG).  Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.

The investigation concerns whether Galapagos and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On February 10, 2021, Galapagos and its development partner Gilead Sciences ("Gilead") issued a press release "announc[ing] the decision to halt the ISABELA Phase 3 clinical studies with the investigational autotaxin inhibitor ziritaxestat in patients with idiopathic pulmonary fibrosis."  Galapagos and Gilead stated that "[t]he decision is based on the recommendations of the Independent Data Monitoring Committee (IDMC) which, following a regular review of unblinded data, concluded that ziritaxestat's benefit-risk profile no longer supported continuing these studies." 

On this news, Galapagos's stock price fell $19.41 per share, or 17.76%, to close at $89.90 per share on February 10, 2021.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

CONTACT:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com 
888-476-6529 ext. 7980

 

Cision
View original content:http://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-galapagos-nv---glpg-301231469.html

SOURCE Pomerantz LLP


ę PRNewswire 2021
All news about GALAPAGOS NV
07/15Galapagos ADRs Down After Study Data
DJ
07/15SECTOR UPDATE : Health Care Stocks Flat To Lower Pre-Bell Thursday
MT
07/15UPDATE : Galapagos Reports Results From Phase 1b Psoriasis Study -- Shares Slump..
MT
07/15GALAPAGOS : N.V., - Galapagos reports positive topline results with selective TY..
PU
07/15GALAPAGOS : N.V., - Galapagos demonstrates early clinical activity with SIK2/3 i..
PU
07/15GALAPAGOS : Drug Shown Safe In Three Clinical Studies
MT
07/15GALAPAGOS' : Psoriasis Drug Shown Safe, Well-Tolerated in Early-Stage Study
MT
07/14GALAPAGOS : demonstrates early clinical activity with SIK2/3 inhibition in infla..
PU
07/14GALAPAGOS : reports positive topline results with selective TYK2 inhibitor GLPG3..
PU
07/14GALAPAGOS : GLPG3667 Shows Positive Results in Psoriasis Patients, Reports Topli..
MT
More news